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Currently, the most effective tuberculosis control method involves case finding and 6months of chemotherapy. There is a need
to improve our understanding about drug interactions, combination activities, and the ability to remove persistent bacteria us-
ing the current regimens, particularly in relation to relapse. We aimed to investigate the therapeutic effects of three main compo-
nents, rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA), in current drug regimens using a modified version of the Cor-
nell mouse model. We evaluated the posttreatment levels of persistentMycobacterium tuberculosis in the organs of mice using
culture filtrate derived fromM. tuberculosis strain H37Rv. When RMP was combined with INH, PZA, or INH-PZA, significant
additive activities were observed compared to each of the single-drug treatments. However, the combination of INH and PZA
showed a less significant additive effect than either of the drugs used on their own. Apparent culture negativity of mouse organs
was achieved at 14 weeks of treatment with RMP-INH, RMP-PZA, and RMP-INH-PZA, but not with INH-PZA, when conven-
tional tests, namely, culture on solid agar and in liquid broth, indicated that the organs were negative for bacteria. The relapse
rates for RMP-containing regimens were not significantly different from a 100% relapse rate at the numbers of mice examined in
this study. In parallel, we examined the organs for the presence of culture filtrate-dependent persistent bacilli after 14 weeks of
treatment. Culture filtrate treatment of the organs revealed persistentM. tuberculosis. Modeling of mycobacterial elimination
rates and evaluation of culture filtrate-dependent organisms showed promise as surrogate methods for efficient factorial evalua-
tion of drug combinations in tuberculosis in mouse models and should be further evaluated against relapse. The presence of cul-
ture filtrate-dependent persistentM. tuberculosis is the likely cause of disease relapse in this modified Cornell mouse model.
Tuberculosis (TB) remains a major killer worldwide and is re-sponsible for approximately two million deaths annually (1).
The main obstacle for successful disease control resides in the
ability ofM. tuberculosis to persist in the host despite host immune
responses and chemotherapy. Prolongedmultidrug antimicrobial
therapy is necessary to achieve a cure, which leads to poor patient
compliance, high relapse rates (7 to 13%), and the emergence of
drug resistance (2). Although short-course TB therapy has been in
clinical use for nearly 4 decades, the drug interactions and the
ability to remove persistent bacteria with the current regimens
have not been clearly demonstrated. Previous work in the murine
Cornell model has shown that after 7 weeks of intensive treatment
with isoniazid (INH) and pyrazinamide (PZA) to induce a latent
infection, the follow-up treatment with rifampin (RMP) alone,
RMP-INH, RMP-PZA, or RMP-INH-PZA exhibited very similar
antituberculosis activities (3). However, another study found that
when mice were treated with INH-RMP-PZA, INH-RMP, or
RMP-PZA for 6 months, the RMP-PZA-treated group demon-
strated significantly lower relapse rates than the INH-RMP-PZA
or INH-RMP group (4). This study suggested that INH antago-
nized the actions of RMP-PZA (4) because INH in the regimen
significantly reduced the Cmax (maximum concentration of drug
in serum) and theAUC (area under the serumconcentration-time
curve) of RMP in themice (4), leading to higher relapse rates. The
antagonism between INH and RMP-PZA was due to a negative
interaction between INH and PZA in the combination, and the
effect was INH dose dependent (5). It was not clear what interac-
tion INH has with each of the components in the regimens. To
provide greater clarity, it is important to identify and evaluate the
level of persistent bacilli after chemotherapy. This information is
of clinical importance, since combination therapy involving
RMP-INH-PZA is commonly employed. Using appropriate drug
combinations has the potential to maximize therapeutic effects
while minimizing side effects of multiple-drug therapy. Further-
more, evaluation of posttreatment persister levels may serve as a
biomarker to predict relapse rates (6). In this study, we examined
the therapeutic effects of each of the components singly and in
two-drug and three-drug combinations using a modified Cornell
mouse model. We evaluated persistent M. tuberculosis using cul-
ture filtrate, which was shown by others (7) to contain resuscita-
tion-promoting factors (RPF) in mouse organs, from a popula-
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tion of mice from a sample of apparently culture-negative organs
after long-term chemotherapy.
MATERIALS AND METHODS
Bacterium and growth conditions. M. tuberculosis strain H37Rv was
mouse passaged and grown in 7H9 medium supplemented with 10%
albumin dextrose complex (ADC; Becton and Dickinson, United King-
dom) containing 0.05% Tween 80 at 37°C without disturbance for 15
days. The culture was subsequently frozen at 70°C for storage. To de-
termine the viable counts prior to infection, CFU countingwas performed
prior to freezing and once again after thawing. CFU counts were carried
out by plating serial 10-fold dilutions of the cultures on 7H11 agar me-
dium supplemented with oleic albumin dextrose complex (OADC; Bec-
ton and Dickinson, United Kingdom). Colonies were counted after incu-
bation of the plates at 37°C for 3 to 4 weeks, and viability was expressed as
log CFU/ml. The cultures were subsequently diluted in phosphate-buff-
ered saline (PBS) and used for inoculations in mice.
Modified Cornell mouse model. Rifampin, isoniazid, and pyrazin-
amide were tested singly or in double (RMP-INH, RMP-PZA, and INH-
PZA) or triple (RMP-INH-PZA) combinations using a modified Cornell
mouse model, which was based on the model previously established at
Cornell University (8, 9). Themodel was conducted using the experimen-
tal design and procedure described below.
(i) Infection of mice. Female BALB/c mice (6 to 8 weeks old) were
obtained from Harlan United Kingdom Ltd. A total of 364 mice were
infected intravenously via the tail vein with 1.2  105 CFU of mouse-
passagedM. tuberculosis strain H37Rv per mouse as described previously
(8, 10, 11). The animal husbandry guidelines and all animal experiments
were performed according to the Animals Scientific Procedures Act, 1986
(an Act of the Parliament of the United Kingdom 1986 c. 14) (Home
Office Project license Number 70/7077) with approval from the St.
George’s, University of London, ethics committee.
(ii) Chemotherapy. As shown in Table 1, mice were randomly allo-
cated into eight groups. The control group consisted of infected and un-
treatedmice; 4 of these were sacrificed 2 h after infection (D0), and then 4
were killed at the beginning of treatment and at 14 and 21 days after
infection (D14 and D21, respectively). The treatment groups were single-
drug treatment groups, each containing 16 mice receiving RMP, INH, or
PZA, respectively, for 8 weeks, and combination groups, each containing
76 mice that were administered RMP-INH, RMP-PZA, INH-PZA, or
RMP-INH-PZA for 14 weeks. Single-drug therapy started 14 days after
infection, when a large bacterial load in the organs (themean CFU counts
reached 107 per lung or spleen) had been achieved with visible symptoms
of disease. Combination therapy started at 21 days after infection. All
groups were treated by daily oral administration (0.2 ml) for 5 days per
week at dosages of 10 mg/kg of body weight RMP, 25 mg/kg INH, or 150
mg/kg PZA. The drug suspensions were prepared freshly for the daily
dose. In the combination containing RMP, RMP was administered 1 h
before the other drugs to avoid drug-drug interactions (4). Immediately
after termination of 14 weeks of chemotherapy, the remaining mice were
administered 0.5 mg/mouse of hydrocortisone acetate by daily oral ad-
ministration for 8weeks to suppress host immune response. The counting
of CFU from lungs and spleens was performed to determine disease re-
lapse.
(iii) Assessment of infection and treatment efficacy.As seen in Table
1, to examine M. tuberculosis infection and baseline CFU counts before
initiation of chemotherapy, 4 untreated control mice were sacrificed at 2
h, 14 days, and 21 days after infection, respectively. For the assessment of
treatment efficacy, 4 mice were sacrificed at 2, 4, 6, and 8 weeks posttreat-
ment for single-drug treatment tomonitor CFU counts. For combination
therapy, a sample of 8 mice was sacrificed at 2, 4, 6, and 8 weeks, and 10
mice were sacrificed at 11 and 14 weeks of treatment (Table 1). Lungs and
spleens from mice were removed rapidly after sacrifice and a sterile au-
topsy was performed. The organs were transferred into 2-ml tubes, each
containing 1 ml sterile distilled water and 2-mm-diameter glass beads.
Lungs and spleens of mice were homogenized using a reciprocal shaker
(Thermo Hybaid Ltd.) for 40 s at a speed of 6.5. CFU counts from each
lung and spleen sample were performed using serial dilutions of the ho-
mogenates. At the 14th week of treatment, the entire-organ homogenates
(the total volume of each organ homogenate was approximately 1.5 ml,
including the organ and 1 ml of water) from the 10 mice were aliquoted
equally into three tubes. Tube 1 was used for CFU counting by addition of
the homogenate to 2 ml of sterile distilled water, followed by plating out
the entire-organ homogenate suspension on 6 selective 7H11 agar plates.
Tube 2 was used for culturing in 5ml of selective Kirchner liquidmedium
by the addition of 200 U/ml polymyxin B, 100 mg/liter carbenicillin, 20
mg/liter trimethoprim, and 10 mg/liter amphotericin B (Selectatab; Mast
Diagnostica GmbH) for 4 weeks with subsequent subculturing of the en-
tire culture onto Löwenstein-Jensen slopes for a further 4 weeks. Tube 3
was used for resuscitation of persistent bacteria. Culture-negative organs
were defined as no colonies grown on 7H11 agar plates and no growth in
selective Kirchner liquid medium following inoculation on Löwenstein-
Jensen slopes.
Selection of RMP- and INH-resistant mutants in mice. At the 4th,
6th, and 8th week posttreatment, mouse lung and spleen homogenates
were plated on 7H11 plates containing RMP or INH concentrated at
2-fold serial dilutions from 1 to 64 mg/liter. Colonies from the plates
containing MICs higher than 4-fold were picked and regrown in 7H9
medium. MIC was retested on RMP or INH containing 7H11 agar plates.
Resuscitation of M. tuberculosis in mouse lungs and spleens. For
resuscitation of M. tuberculosis grown in mouse organs, culture filtrates
containing RPF were used as described previously (6, 7). M. tuberculosis
H37Rv was grown in 7H9 medium for 15 to 20 days until an optical
density of 1 to 1.5 was reached. The cultures were harvested by centrifu-
gation at 3,000  g for 15 min and sterilized by filtration with a 0.2-m
filter (Sartorius) twice. The sterilized culture filtrates were made selective
TABLE 1 Mouse tuberculosis experimental design
Treatment
groupa
Total no.
of miceb D0 D14 D21 W2 W4 W6 W8 W11 W14 W22c
Control 12 4 4 4
RMP 16 4 4 4 4
INH 16 4 4 4 4
PZA 16 4 4 4 4
RMP-INH 76 8 8 8 8 10 10 24
RMP-PZA 76 8 8 8 8 10 10 24
INH-PZA 76 8 8 8 8 10 10 24
RMP-INH-PZA 76 8 8 8 8 10 10 24
a Mice were intravenously infected on day 0 (D0). Treatment commenced 14 days after infection for single-drug therapy (D14) and 21 days after infection for combination therapy
(D21). Dosages for each drug were the following: RMP, 10 mg/kg; INH, 25 mg/kg; and PZA, 150 mg/kg.
b Total mice includes mice that were infected and treated and excludes mice that died of natural causes during the course of treatment.
c Eight weeks of hydrocortisone treatment after 14 weeks of treatment.
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by addition of 200,000 U/liter polymyxin B, 100 mg/liter carbenicillin, 20
mg/liter trimethoprim, and 10 mg/liter amphotericin B (Selectatab; Mast
DiagnosticaGmbH) and immediately used for broth counting of themost
probable number (MPN) of the bacilli (7). Broth counting of lungs and
spleens after 14 weeks of combination therapy was performed with serial
10-fold dilutions in triplicate in which 0.5 ml of tissue homogenates was
added to 4.5ml of the culture filtrates. At 10-day intervals over a 2-month
period of incubation at 37°C, the broth cultures were examined for visible
turbidity changes. Growth of M. tuberculosis in turbid tubes was con-
firmed by colonial morphology on 7H11 agar plates. The MPN of viable
bacilli was then estimated frompatterns of positive and negative tubes (7).
The absence of microorganisms other than mycobacteria from turbid
tubes was confirmed by plating on blood agar medium (Oxoid) and Sab-
ouraud dextrose agar (Oxoid). In order to assess the sterility of culture
filtrates free of M. tuberculosis, tubes containing culture filtrates were in-
cubated at 37°C for 2months to ensure the absence ofM. tuberculosis from
the culture filtrates.
Statistical analysis. A simple model for mono-exponential bacterial
growth and elimination (12) (Fig. 1) was fitted to the profiles of CFU
versus time obtained experimentally. As simultaneously occurring expo-
nential replication and death rates cannot be differentiated with this type
of data, an exponential rate constant, knet, was estimated separately before
treatment began (knet_no_drug, which would be a net positive value) and
during treatment (knet_with_drug, whichwould be a negative value). During
therapy, knet is a first-order elimination rate constant which can be inter-
preted as the slope of the modeled line fit through the logarithmic trans-
formation of the data (with units of these data being per week). Parameter
estimation was carried out with nonlinear regression using the nonlinear
least-squares optimization function “lsqnonlin” as part of the “pracma”
package in the R statistical software language, with an objective function
weighted by 1/(predicted value)2. Standard errors of parameter estimates
were calculated using themethod outlined by Landaw andDiStefano (13),
with the Jacobian of model parameter sensitivities estimated using a nu-
merical central difference method. The data sets, comprised from multi-
ple individual subject animals, were treated as a naive pool for data anal-
ysis purposes (14) rather than using the average of the data at each time
point. The significance of differences betweenmodel parameter estimates
under different therapies was examined with pairwise Z-tests incorporat-
ing a Bonferroni correction of 21, where P values of 0.002 would be
considered significant. The significance of differences between the relapse
rates was determined with pairwise Fisher’s exact tests with a Bonferroni
correction of 6, with P values of0.008 considered significant.
RESULTS
Survival of mice. During treatment, 4 mice in the RMP-INH
group died (1 at 9 weeks, 1 at 10 weeks, and 2 at 12 weeks), 2 mice
in the RMP-PZA group died (1 at 10weeks and 1 at 12weeks), and
3 mice died in the INH-PZA group died (1 at 9 weeks, 1 at 10
weeks, and 1 at 13 weeks). The reason for the death was unknown
but was most likely due to natural causes, such as tumor develop-
ment or neurological disorders, and was unrelated to tuberculosis
or treatment. As the time of deathwas uncertain and did not occur
at the sampling time point, organ bacterial counts were not deter-
mined from these animals. No mortality was observed during the
course of single-drug and RMP-INH-PZA treatments.
Treatment with RMP, INH, and PZA singly and in two-drug
or three-drug combination in amodifiedCornellmousemodel.
We investigated the effect of RMP, INH, and PZA singly and in
double and triple combinations on the rates of bacterial eradica-
tion and relapse in a modified Cornell mouse model. The single
dose of the drugs was tested in the animals for 8 weeks and termi-
nated before resistant strain emergence (15). As shown in Tables 2
and 3 and Fig. 2, RMP at 10 mg/kg, INH at 25 mg/kg, and PZA at
150 mg/kg exhibited modest rates of bacterial eradication in both
lungs and spleens, showing 99% kill (2-log reduction) at around 8
weeks. The exponential rate constants (logarithmic base 10) for
net bacterial elimination during treatment (knet_with_drug) for
RMP, INH, and PZAwere0.21,0.27, and0.26 for lungs and
0.31,0.29, and0.26 for spleens (Table 4), respectively. No-
tably, the drop inCFU counts in both lungs and spleens during the
first 2 weeks of treatment with the singly dosed drugs was mini-
mal, although over the complete time course of therapy a clear
mono-exponential decline in CFU counts was observed. No
RMP- or INH-resistant strains were isolated from 4 to 8 weeks of
treatment. In addition, there was no significant difference in ac-
tivities among the single-drug treatments (see Tables S1 and S2 in
the supplemental material). Interestingly, treatment with RMP
combined with INH (Fig. 2A and E) or PZA (Fig. 2B and F) accel-
erated the rate of bacterial eradication, showing 99% kill (Table 2
and 3) at 4 weeks of treatment for RMP-INH and at about 3 weeks
FIG 1 Simple mathematical model for exponential growth and decline of
bacteria.
TABLE 2 Bactericidal and sterilizing activities of experimental regimens against M. tuberculosis in mouse lungs
Infection or treatment
time pointa
Activity (mean log CFU per lung SD) of:
Control RMP INH PZA RMP-INH RMP-PZA INH-PZA RMP-INH-PZA
D0 4.38 0.04
D14 6.86 0.13
D21 7.04 0.01
W2 6.48 0.14 6.83 0.25 6.87 0.13 6.05 0.07 5.66 0.13 6.84 0.04 6.10 0.16
W4 5.40 0.15 5.57 0.37 5.32 0.15 5.05 0.07 4.26 0.08 5.46 0.24 4.63 0.17
W6 5.37 0.29 5.27 0.70 5.19 0.35 3.64 0.12 3.46 0.18 5.16 0.04 3.81 0.14
W8 5.18 0.13 4.89 0.40 5.05 0.15 3.12 0.21 2.73 0.22 3.83 0.07 2.32 0.24
W11 1.20 0.27 0.77 0.48 2.54 0.12 0.63 0.70
W14b 0 0 1.82 0.42 0
a D0, 2 h postinfection; D14, 14 days postinfection; D21, 21 days postinfection; W2, week 2 posttreatment.
b CFU counts were derived from one-third of the tissue homogenate, and the limit of detection was 3 CFU/lung.
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for RMP-PZA, with the estimation of knet_with_drug at 0.53 and
0.51 for lungs and5.2 and0.43 for spleens (Table 4), respec-
tively. All of the combined therapies were significantlymore effec-
tive than the single therapy (see Tables S1 and S2). As seen in
Tables 2 and 3 and Fig. 2C and G, 99% kill with the RMP-INH-
PZA combination was achieved at about 3 weeks for both lungs
and spleens, showing elimination rate constants (0.51 for lung
and0.48 for spleen) similar to those of RMP-INH or RMP-PZA
(Table 4). There was no significant difference in efficacies among
these RMP-containing regimens against M. tuberculosis in this
mouse model (see Tables S1 and S2). All of the RMP-containing
combinations achieved undetectable M. tuberculosis CFU counts
(Tables 2 and 3) and negative broth growth in selective Kirchner
liquid medium in murine lungs and spleens at 14 weeks of treat-
ment. However, when INHwas combined with PZA (Fig. 2D and
H), there was no noticeably increased initial kill compared to that
of each of the single drugs until 4 weeks of treatment, followed by
a reduction of CFU count showing a 99% kill at 5.6 weeks post-
treatment (Table 2) for lungs and 4 weeks for spleens (Table 3).
This was reflected in the estimates for knet_with_drug for the INH
and PZA combination, which was0.42 and0.44 for lungs and
spleens, respectively (Table 4). Although the INH and PZA com-
binations failed to achieve undetectable M. tuberculosis CFU
counts in murine lungs after 14 weeks of treatment (Fig. 2D and
H), the difference in efficacies between the single-drug treatment
and the combination was significant (see Tables S1 and S2).
Relapse rate of treatment with RMP-INH, RMP-PZA, and
RMP-INH-PZA in the modified Cornell mouse model. After 8
weeks of immunosuppression with high-dosage steroid, disease
relapse rates for the treatments with two- and three-drug were
determined by the percentage of mice that developed positive M.
tuberculosis CFU counts in lungs, spleens, or both. The organ re-
lapse proportions for the four regimens are shown in Table 5. The
treatment with the regimens of RMP-INH, RMP-PZA, and RMP-
INH-PZA yielded similar relapse rates at 85, 77.3, and 87.5%,
respectively. These relapse rates were not significantly different
among the three-drug regimens or from a 100% relapse rate (P
0.002 by Fisher’s exact test, including Bonferroni correction for
multiple pairwise tests). The INH and PZA combination did not
produce a negative organ CFU count at the termination of the
14-week treatment (Tables 2 and 3).
Determination of persisters after treatment with four drug
regimens. In order to determine the effect of the four combina-
tion regimens on the posttreatment level of persisters, we analyzed
lung and spleen homogenates at 14 weeks posttreatment usingM.
tuberculosis culture filtrate resuscitation (6). As shown in Table 6,
at 14 weeks posttreatment, although CFU counts and growth in
Kirchner liquid medium were negative for the drug regimens
INH-RMP, RMP-PZA, and INH-RMP-PZA, there were signifi-
cant amounts of culture filtrate-dependent persisters present in
lungs and spleens (1.89 log cells/lung and 2.09 log cells/spleen
for RMP-PZA, 2 log cells/lung and 2.18 log cells/spleen for INH-
RMP, and 1.94 log cells/lung and 2.12 log cells/spleen for INH-
RMP-PZA). After INH-PZA treatment, there were 4-log culture
filtrate-resuscitated bacilli in both lungs and spleens. If we exclude
CFU count-positive bacilli, there were still 4-log culture filtrate-
dependent persisters in the organs of INH-PZA-treated mice.
DISCUSSION
In this study, we reevaluated the current TB treatment regimen
and studied the drug interactions by comparing the bacterial elim-
ination rates, the number of culture filtrate-dependent bacteria
present at treatment completion, and relapse rates with different
therapies in a mouse tuberculosis treatment model based on the
model established at Cornell University over a half century ago (8,
9). This model enables us to determine anti-TB activities of com-
bination regimens and, importantly, to measure relapse rates. It is
characterized by the inoculation of a large number of bacteria
intravenously to initiate an infection and the treatment of the
disease once the infection has been established (2 to 3 weeks
postinfection). In this model, an intensive treatment is able to
render mouse organs culture negative on agar plates and in broth
culture lacking culture filtrate, but it fails to prevent relapse (10,
11).However, these apparently culture-negative organs contained
viable bacteria that could be cultivated by supplementing broth
media with culture filtrate (6) containing RPF (7). Significantly,
we found that when RMPwas combined with INH, PZA, or INH-
PZA, significant additive activities were observed compared to
each of the single-drug treatments. However, the combination of
INH and PZA showed a less significant additive effect than either
of the single-drug treatments. The combination regimens of
RMP-INH, RMP-PZA, and RMP-INH-PZA exhibited equivalent
treatment efficacies with very similar relapse rates which could
not actually be differentiated from a 100% relapse rate, while
INH-PZA failed to render organ culture negative after 14 weeks of
treatment. Rifampin-containing regimens reduced the number of
culture filtrate-dependent persisters to a greater extent than INH-
TABLE 3 Bactericidal and sterilizing activities of experimental regimens against M. tuberculosis in mouse spleens
Infection or treatment
time pointa
Activity (mean log CFU per spleen SD) of:
Control RMP INH PZA RMP-INH RMP-PZA INH-PZA RMP-INH-PZA
D0 5.32 0.04
D14 7.06 0.01
D21 7.22 0.21
W2 6.66 0.06 6.85 0.15 6.45 0.51 5.59 0.14 5.07 0.12 6.14 0.17 5.57 0.15
W4 5.49 0.10 5.58 0.30 5.89 0.10 4.52 0.14 3.99 0.22 5.29 0.25 4.15 0.10
W6 4.90 0.24 5.19 0.19 5.46 0.24 3.52 0.20 2.71 0.45 5.01 0.08 3.15 0.29
W8 4.80 0.24 4.99 0.16 5.06 0.08 3.01 0.11 1.95 0.19 4.57 0.06 1.99 0.07
W11 0.78 0.50 0.64 0.69 2.53 0.43 0.73 0.49
W14b 0 0 1.52 0.50 0
a D0, 2 h postinfection; D14, 14 days postinfection; D21, 21 days postinfection; W2, week 2 posttreatment.
b CFU counts were derived from one-third of the tissue homogenate, and the limit detection was 3 CFU/lung.
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FIG 2 Treatment profiles of M. tuberculosis H37Rv with RMP, INH, and PZA singly or in combination in the modified Cornell mouse model. The results of a
single experiment are shown with viability expressed as log CFU counts per lung or per spleen. Mice were infected intravenously at week 2 or 3, and the
infection was allowed to progress for 2 or 3 weeks prior to treatment with RMP, INH, and PZA singly or in combination, indicated by solid black arrows, for 14
weeks (weeks 0 to 14). At weeks 2, 4, 6, 8, 11, and 14 posttreatment, CFU counts in the organs from each treatment group were estimated. Steroid treatment was
started immediately after the termination of 14 weeks of antibiotic treatment, as indicated by arrows containing white lines. obs, observed; pred, predicted. (A)
Treatment with RMP, INH, and RMP-INH in lungs. (B) Treatment with RMP, PZA, and RMP-PZA in lungs. (C) Treatment with RMP, INH, PZA, and
RMP-INH-PZA in lungs. (D) Treatment with INH, PZA, and INH-PZA in lungs. (E) Treatment with RMP, INH, and RMP-INH in spleens. (F) Treatment with
RMP, PZA, and RMP-PZA in spleens. (G) Treatment with RMP, INH, PZA, and RMP-INH-PZA in spleens. (H) Treatment with INH, PZA, and INH-PZA in
spleens.
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PZA but did not eliminate them frommouse organs by the end of
14 weeks of treatment.
In humans, the key for treatment success depends on the bac-
tericidal drugs INH and RMP, which rapidly kill actively replicat-
ing bacilli in cavities and control disease progression (16) within
the first 2 months of chemotherapy. This is defined by negative
acid-fast staining in sputum. In fact, bactericidal drugs such as
INH exhibit bactericidal activity during the first 2 days of mono-
chemotherapy (17). The need for prolonged treatment is due to
the emergence of persistent bacilli which may arise in the hetero-
geneity of host environments (18). These persistent tubercle ba-
cilli are undetectable by the traditional microbiological methods
and become profoundly tolerant to bactericidal drugs (10). Ster-
ilizing drugs such as PZA andRMPcontribute to shortening of the
treatment duration (18). However, in our study comparing elim-
ination rate constants for monotherapies in mice, there was no
significant difference between RMP, INH, or PZA. There was no
superior bactericidal activity of INH, which contrasts with the
effect of INH in humans. This indicates that treatment profiles are
different between mice and humans.
Synergistic drug interactions have not been demonstrated in
the treatment of TB inmice. It is generally accepted thatmore than
a 2-log kill compared to the single drug defines a synergistic com-
bination (19). Here, we showed that enhanced bactericidal activ-
ities were achieved when RMP was combined with INH or PZA.
Estimates of the elimination rate constant for all the combinations
were significantly faster (P 0.0001) than those of all single drugs
(see Tables S1 and S2 in the supplemental material), showing a
99% kill of the bacilli (a 2-log kill) achieved 4 to 5 weeks earlier
than that with monotherapies. The activities of the combinations,
namely, RMP-INH, RMP-PZA, and RMP-INH-PZA, shown by
the value of the exponential elimination rate constant (Table 4)
demonstrated significant additive interactions on the original
scale. Therefore, it is interesting that the INH-PZA combination
showed less enhanced effect than the singly dosed drugs at the
earlier stage of treatment when there was a large number of ac-
tively growing organisms (10), and its increased efficacy com-
pared to the monotherapies was more apparent after 6 weeks of
treatment. This was in agreement with the previous findings that
the INH and PZA combination was more efficacious than the
single drug in the reduction of organ bacterial counts and preven-
tion of relapse rates in mice (8, 20) and in humans (21–23). The
efficacies of all RMP-containing regimens (INH-RMP, RMP-
PZA, and INH-RMP-PZA) in mouse tuberculosis treatment were
very similar (P 0.05), as shown by the similarity of the elimina-
TABLE 4 Estimates of exponential rate constants during pretreatment and treatment of mouse lungs and spleens
Treatmenta
knet value(week
1) by sample sourceb
Lung Spleen
knet_no_drug knet_with_drug knet_no_drug knet_with_drug
Est %RSE Est %RSE Est %RSE Est %RSE
RMP 1.03 1.99 0.21 8.22 1.08 3.15 0.31 6.09
INH 1.03 1.99 0.27 10.37 1.08 3.15 0.29 6.35
PZA 1.03 1.99 0.26 9.05 1.08 3.15 0.26 5.92
RMP-INH 0.85 5.05 0.53 2.61 0.58 0.91 0.52 2.15
RMP-PZA 0.85 5.05 0.51 1.65 0.58 0.91 0.43 4.95
INH-PZA 0.85 5.05 0.42 3.00 0.58 0.91 0.44 4.38
RMP-INH-PZA 0.85 5.05 0.51 2.91 0.58 0.91 0.48 3.23
a Single-drug treatments lasted 8 weeks and double- and triple-drug treatments lasted 14 weeks.
b Est, estimate; %RSE, percent relative standard error.
TABLE 5 Relapse of mice after two- or three-drug treatment
Culture source or
parameter measured
Value fora:
RMP-INH RMP-PZA RMP-INH-PZA
Positive culture
source (no.)
Spleen only 8 6 15
Lung only 5 4 1
Both 4 7 5
Neither 3 5 3
Total no. of mice with
positive cultures
17 17 21
Total no. of mice 20 22 24
Relapse (%) 85 77.3 87.5
a P values of relative relapse rates determined by Fisher’s exact test were 0.7 (RMP-INH/
RMP-PZA), 1.0 (RMP-INH/RMP-INH-PZA), and 0.45 (RMP-PZA/RMP-INH-PZA)
with Bonferroni correction. A P value of0.008 was considered significant.
TABLE 6 Resuscitation of M. tuberculosis H37Rv in mouse lungs and
spleens of a modified Cornell mouse model after treatment with
different drug regimens
Drug regimena
Sample sourceb
Lung Spleen
Plate count
Broth
count RPF
Plate
count
Broth
count RPF
RMP-PZA 0 1.89 0.12 0 2.09 0.29
INH-RMP 0 2.00 0.14 0 2.18 0.32
INH-RMP-PZA 0 1.94 0.14 0 2.12 0.26
INH-PZA 1.82 0.42 4.10 0.09 1.52 0.5 4.07 0.15
a Fourteen-week treatment.
b Plate counts were determined as CFU counts of the organ homogenies (n 10) on
7H11 agar plates (mean log CFU/organ standard deviations). CFU counts were
derived from one-third of the tissue homogenate and calculated to represent counts of
the entire organ. The limit of detection was 3 CFU/organ. Broth count RPF were
determined by MPN of the diluted organ homogenies (n 10) with the culture filtrates
(mean log MPN/organ standard deviations). Broth counts were derived from one-
third of the tissue homogenate and was calculated to represent the MPN of the entire
organ. The limit of detection was 10 MPN/organ.
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tion rate constants, which confirmed previous findings (3, 4),
while INH-PZA therapy was less effective than other combination
therapies (P  0.001) (5). At the end of 14 weeks of treatment,
lungs and spleens of mice treated with RMP-INH, RMP-PZA, or
RMP-INH-PZA became CFU count and broth count negative;
conversely, the INH and PZA combination failed to achieve cul-
ture negativity in themouse organs. After 8 weeks of steroid treat-
ment, tubercle bacilli were found in the organs of mice treated
with RMP-INH, RMP-PZA, or RMP-INH-PZA. Although the
elimination rates of the rifampin-containing regimens (RMP-
INH, RMP-PZA, and RMP-INH-PZA) displayed significant dif-
ferences from that for INH-PZA (the latter regimen having failed
to achieve culture negativity), their relapse rates could not be dif-
ferentiated from a 100% relapse rate at the numbers of mice ex-
amined in this study. This is attributable to the presence of persis-
tent bacteria in the RMP-containing regimens which could only
be resuscitated by culture filtrate (Table 6). This observation co-
incided with the previous finding that early bactericidal activities
of certain novel drug regimens were not necessarily predictive of a
sterilizing effect (24), which may be attributed to the inability of
the drug regimens to eliminate the persistent bacilli which were
undetectable using our traditional microbiological methods. Re-
cently, we showed that faster elimination rates derived from high-
dose RMP treatment led to the elimination of persistent bacteria,
and this contributed to a shortened chemotherapy and a reduced
relapse rate (6). It is not known if the elimination rate of culture
filtrate-dependent bacteria is a likely surrogate measure of the
sterilizing activity of the regimens, as this has not been deter-
mined. RMP-containing regimens resulted in faster elimination
rates than INH-PZA against plate-cultivable and reduced culture
filtrate-dependent subpopulations at 14 weeks of treatment.
Clearly further study is required to demonstrate if the elimination
rate of culture filtrate-dependent bacteria is a better surrogate for
sterilizing effect.
Themajor caveat of this studywas the relatively short period of
chemotherapy in which INH-PZA failed to achieve CFU count-
negative mouse organs. This made it difficult to compare relapse
rates of all the treatment regimens. It is likely that a difference in
the sterilizing activity of these regimens would emerge with longer
durations of treatment. Future work aiming to use a larger num-
ber of mice and longer treatment duration would illustrate more
clearly the relationship between elimination rate and relapse
among different drug regimens.
Bacterial population dynamics in infected animals is expected
to be complex and related to the density and composition of the
infecting population. In this study, the route of infection was sys-
temic, and it was performed according to a previously established
method (8, 9). Previous studies showed that intravenous infection
of M. tuberculosis in mice led to slower disease progression in
lungs (25) in spite of a high level of systemic immunity. However,
low-dose aerosol infection resulted in substantially greater viru-
lence of M. tuberculosis in mouse lungs (25). In aerosol-infected
mice, small numbers of bacilli were seeded in the lung, and these
then multiply into larger populations (25), presumably with
smaller subpopulations of persistent organisms. It has been shown
that slower bactericidal rates of combination regimenswere found
in intravenously infected mice with a higher relapse rate than
aerosol-infected animals (26). The difference might be due to dif-
ferent immune responses produced between intravenously and
aerosol-infected animals. It is not known if different routes of
infection affect the level of culture filtrate-dependent persisters.
Future work will be conducted to compare persistentM. tubercu-
losis levels in mice using respiratory and systemic infections.
It has been shown that antagonism occurred between INH and
the RMP-PZA combination in the treatment of tuberculosis in
mice (4). The authors suggested that the antagonistic effect was
partially derived from the interaction of INH with RMP, as the
addition of INH significantly reduced the Cmax and AUC of RMP
(4). There was also a negative interaction between INH and PZA
againstM. tuberculosis (5) in mice when a higher dose of INHwas
used. In contrast, a separate study showed that RMP-PZAwas less
effective than the RMP-INH-PZA combination in mouse models
with both aerosol and intravenous infections, indicating that the
inclusion of INH in the regimen showed no negative interaction
with RMP-PZA (26). In observations of CFU counts over time
with RMP-INH, RMP-PZA, and RMP-INH-PZA, RMP-PZA
treatment showed increased reduction in CFU counts com-
pared to RMP-INH and RMP-INH-PZA, especially at weeks 2,
4, and 6 of treatment (Fig. 2), indicating that INH was slightly
antagonistic. However, our data demonstrated that this antag-
onistic effect when INH is added to the RMP-PZA regimen was
not significant based on a comparison of the elimination rate
constants estimated from the profiles of bacterial elimination
over time; the knet_with_drug was0.51 for RMP-PZA and0.51
for RMP-INH-PZA (a P value of 0.002 indicates significant
difference). We also observed that the INH-PZA combination
was not antagonistic against M. tuberculosis compared to the ac-
tivities of each single drug. The differences in drug interaction of
the current regimens seen from different studies may be attribut-
able to different experimental conditions, such as the use of dif-
ferent M. tuberculosis strains, mouse species, routes of infection,
and length of treatment used by different research groups (26).
Importantly, our demonstration ofRMP-containing regimens be-
ing superior to an RMP-free regimen againstM. tuberculosis in the
modified Cornell mouse model indicated the essential role RMP
plays in the current regimen to treat tuberculosis disease. How-
ever, the relationship between elimination rate, MPN counts, and
relapse rates requires further evaluation across a broader range of
(possibly non-RMP-containing) regimens.
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